OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Kolibaba on Efficacy of Entospletinib in Mantle Cell Lymphoma

January 4th 2017

Kathryn Kolibaba, MD, co-chair, Hematology Research Committee, US Oncology Research, discusses why the Syk inhibitor entospletinib demonstrates efficacy in patients with mantle cell lymphoma (MCL).

Dr. Carbone on Effectiveness of Different Lung Cancer Therapies

January 4th 2017

David Carbone, MD, PhD, director of the James Thoracic Center, and professor of Medicine at The Ohio State University Comprehensive Cancer Center, discusses the effectiveness of different therapies to treat patients with lung cancer.

Dr. Kris on the Future of Immunotherapy and Targeted Therapy in Lung Cancer

January 4th 2017

Mark G. Kris, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses what the future holds for the development of immunotherapy and targeted therapy in the treatment of patients with lung cancer.

Dr. Brufsky on Cobimetinib Plus Paclitaxel in TNBC

January 4th 2017

Adam M. Brufsky, MD, PhD, professor of Medicine, associate chief of Hematology/Oncology, co-director of the Comprehensive Breast Care Center, associate director of Clinical Investigation, University of Pittsburgh, discusses combining cobimetinib and paclitaxel as a first-line treatment in patients with advanced triple-negative breast cancer.

Dr. Zelenetz on Treatment for Patients With CLL Who Fail on Ibrutinib or Idelalisib

January 4th 2017

Andrew D. Zelenetz, MD, PhD, medical director of Quality Informatics at Memorial Sloan Kettering Cancer Center, discusses treatment options for patients with chronic lymphocytic leukemia who fail on ibrutinib or idelalisib.

Dr. Petrylak on Novel Immunotherapy Research in Bladder Cancer

January 4th 2017

Daniel P. Petrylak, MD, professor of Medicine and Urology, Yale Cancer Center, discusses the recent explosion of immunotherapy research in the treatment landscape of bladder cancer.

Dr. Patnaik on Activity of SL-401 in Chronic Myelomonocytic Leukemia

December 31st 2016

Mrinal Patnaik, MBBS, hematologist, Mayo Clinic, discusses the encouraging results seen in a phase II trial evaluating the activity of SL-401 in patients with advanced, high risk myeloproliferative neoplasms, including chronic myelomonocytic leukemia.

Dr. Puzanov on Management of Adverse Events in Melanoma

December 30th 2016

Igor Puzanov, MD, director, Early Phase Clinical Trials Program, chief of Melanoma, coleader, CCSG Experimental Therapeutics Program, professor of Oncology, Department of Medicine, Roswell Park Cancer Institute, discusses ways to manage patients with melanoma who may experience adverse events in response to treatment with immunotherapy.

Dr. Goy on Bortezomib in MCL Treatment

December 30th 2016

Andre Goy, MD, MS, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses the history of bortezomib as a treatment for patients with mantle cell lymphoma.

Dr. Hamid on Patient Selection for Immunotherapy Regimens in Melanoma

December 30th 2016

Omid A. Hamid, MD, chief, Translational Research and Immunotherapy, director, Melanoma Therapeutics, The Angeles Clinic and Research Institute, discusses how to accurately select patients who are likely to have durable and long responses with single-agent immunotherapy versus combination treatment.

Dr. Mascarenhas on the MPD-RC 112 Study in PV and ET

December 30th 2016

John Mascarenhas, MD, associate professor of Medicine, Mount Sinai School of Medicine, discusses the results from the interim analysis of the MPD-RC 112 study, which compared frontline pegylated interferon-alpha-2a with hydroxyurea in the treatment of patients with high risk polycythemia vera and essential thrombocythemia.

Dr. Saenger on Immunotherapy Combinations in Melanoma

December 30th 2016

Yvonne Saenger, MD, director of Melanoma Immunotherapy at Columbia University Medical Center, discusses immunotherapy combinations in melanoma.

Dr. Wolchok on Progress After Anti-PD-1 Monotherapy in Melanoma

December 29th 2016

Jedd D. Wolchok, MD, PhD, chief, Melanoma and Immunotherapeutics Service, Department of Medicine and Ludwig Center at Memorial Sloan Kettering Cancer Center, 2014 Giant of Cancer Care in Melanoma, discusses an ongoing clinical trial that will explore optimal treatments for patients with melanoma who fail on a PD-1 inhibitor as a single agent.

Dr. Birrer on Patient Preferences for Cervical Cancer Treatment

December 29th 2016

Michael Birrer, MD, PhD, director of Medical Gynecologic Oncology at Massachusetts General Hospital, discusses patient preferences for cervical cancer treatment, as well as the demographics of this population.

Dr. Neelapu on Interim Results of the Phase II ZUMA-1 Study in DLBCL

December 29th 2016

Sattva S. Neelapu, MD, associate professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses interim results of the phase II ZUMA-1 study in patients with diffuse large B-cell lymphoma.

Dr. Daver on Immune Checkpoint Pathways in AML

December 28th 2016

Naval Daver, MD, assistant professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses research evaluating different immune checkpoint pathways in patients with acute myeloid leukemia.

Dr. Luke on Ongoing Studies With Immunotherapy in Melanoma

December 28th 2016

Jason J. Luke, MD, an assistant professor of Medicine at the University of Chicago Medicine, discusses ongoing studies exploring immunotherapy for the treatment of patients with melanoma.

Dr. Vokes on Selecting Nivolumab or Pembrolizumab for Head and Neck Cancer Treatment

December 28th 2016

Everett Vokes, MD, John E. Ultmann Professor of Medicine and Radiation Oncology, physician-in-chief, University of Chicago Medical Center, chair, Department of Medicine, University of Chicago Medicine, discusses how to choose between nivolumab (Opdivo) and pembrolizumab (Keytruda) for second-line treatment for patients with head and neck cancer.

Dr. Burtness on Treatment Approaches in HPV-Positive Head and Neck Cancer

December 27th 2016

Barbara Burtness, MD, professor of Medicine, Yale Cancer Center, discusses current treatment approaches for patients with human pappillomavirus (HPV)-positive head and neck cancer, as well as potential changes for those regimens.

Dr. Puzanov on Sequencing Targeted Therapy and Immunotherapy in Melanoma

December 27th 2016

Igor Puzanov, MD, director, Early Phase Clinical Trials Program, chief of Melanoma, coleader, CCSG Experimental Therapeutics Program, professor of Oncology, Department of Medicine, Roswell Park Cancer Institute, discusses an ongoing study exploring the optimal sequence of immunotherapy agents and targeted therapies for patients with melanoma.